Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 VistaGen TherapeuticsRedHill BiopharmaImmunicTonix PharmaceuticalsNextCure
SymbolNASDAQ:VTGNNASDAQ:RDHLNASDAQ:IMUXNASDAQ:TNXPNASDAQ:NXTC
Price Information
Current Price$2.05$7.01$14.21$0.98$9.42
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.31.41.81.81.6
Analysis Score3.53.54.53.53.2
Community Score2.92.92.82.82.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.81.71.7
Earnings & Valuation Score0.00.60.61.30.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$5.67$20.00$59.56$4.00$22.55
% Upside from Price Target176.42% upside185.31% upside319.11% upside308.16% upside139.34% upside
Trade Information
Market Cap$293.85 million$342.40 million$300.80 million$317.44 million$259.99 million
Beta0.521.712.211.57-0.4
Average Volume3,405,376557,992226,55236,696,871224,833
Sales & Book Value
Annual RevenueN/A$6.29 millionN/AN/A$6.35 million
Price / SalesN/A51.71N/AN/A40.94
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.12) per share$2.74 per share$5.77 per share$1.11 per share$14.13 per share
Price / BookN/A2.56N/AN/A0.67
Profitability
Net Income$-20,770,000.00$-42,300,000.00$-34,930,000.00$-28,620,000.00$-33,740,000.00
EPS($0.50)($1.40)($4.52)($19.33)($2.15)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-142.81%N/AN/AN/A
Return on Equity (ROE)N/A-152.19%-46.33%-107.52%-10.00%
Return on Assets (ROA)-272.12%-45.96%-42.50%-96.64%-9.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A2.79%N/AN/A0.01%
Current Ratio0.82%1.80%17.13%14.17%51.73%
Quick Ratio0.82%1.64%17.13%14.17%51.73%
Ownership Information
Institutional Ownership Percentage3.13%20.36%41.26%2.23%66.30%
Insider Ownership Percentage13.67%N/A12.07%0.15%9.05%
Miscellaneous
Employees11182281690
Shares Outstanding143.34 million46.40 million21.17 million323.92 million27.60 million
Next Earnings Date7/5/2021 (Estimated)5/26/2021 (Estimated)5/14/2021 (Estimated)5/11/2021 (Estimated)5/6/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
A Trio of Net Current Asset Value Stock Picks - GuruFocus.comA Trio of Net Current Asset Value Stock Picks - GuruFocus.com
gurufocus.com - April 14 at 3:19 AM
Reviewing NextCure (NASDAQ:NXTC) and Kintara Therapeutics (NASDAQ:KTRA)Reviewing NextCure (NASDAQ:NXTC) and Kintara Therapeutics (NASDAQ:KTRA)
americanbankingnews.com - April 13 at 8:50 PM
A Trio of Net Current Asset Value Stock Picks - Yahoo FinanceA Trio of Net Current Asset Value Stock Picks - Yahoo Finance
finance.yahoo.com - April 13 at 5:17 PM
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - BioSpaceNextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - BioSpace
biospace.com - April 12 at 5:26 AM
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - GlobeNewswireNextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - GlobeNewswire
globenewswire.com - April 10 at 9:12 AM
Contrasting NextCure (NASDAQ:NXTC) and Spero Therapeutics (NASDAQ:SPRO)Contrasting NextCure (NASDAQ:NXTC) and Spero Therapeutics (NASDAQ:SPRO)
americanbankingnews.com - April 9 at 4:20 AM
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference - Yahoo FinanceNextCure to Present at the 20th Annual Needham Virtual Healthcare Conference - Yahoo Finance
finance.yahoo.com - April 7 at 6:11 PM
NextCure to Present at the 20th Annual Needham Virtual Healthcare ConferenceNextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 7 at 6:11 PM
Are Institutions Heavily Invested In NextCure, Inc.s (NASDAQ:NXTC) Shares? - Yahoo FinanceAre Institutions Heavily Invested In NextCure, Inc.'s (NASDAQ:NXTC) Shares? - Yahoo Finance
finance.yahoo.com - April 2 at 4:12 PM
Are Institutions Heavily Invested In NextCure, Inc.s (NASDAQ:NXTC) Shares?Are Institutions Heavily Invested In NextCure, Inc.'s (NASDAQ:NXTC) Shares?
finance.yahoo.com - April 2 at 11:11 AM
Myeloid Therapeutics Appoints Elaine Jones, Ph.D., to its Board of Directors - Odessa AmericanMyeloid Therapeutics Appoints Elaine Jones, Ph.D., to its Board of Directors - Odessa American
oaoa.com - March 31 at 8:44 PM
NextCure, Inc. (NASDAQ:NXTC) Receives Average Rating of "Hold" from AnalystsNextCure, Inc. (NASDAQ:NXTC) Receives Average Rating of "Hold" from Analysts
americanbankingnews.com - March 24 at 5:40 AM
Form POS AM NextCure, Inc. - StreetInsider.comForm POS AM NextCure, Inc. - StreetInsider.com
streetinsider.com - March 5 at 5:42 PM
NextCure raised to buy at Truist on research updates - Seeking AlphaNextCure raised to buy at Truist on research updates - Seeking Alpha
seekingalpha.com - March 5 at 5:42 PM
NEXTCURE : Managements Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - marketscreener.comNEXTCURE : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - marketscreener.com
marketscreener.com - March 4 at 9:08 PM
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswireNextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire
globenewswire.com - March 4 at 9:08 PM
NextCure to Host Virtual R&D Update Event on March 4, 2021 Nasdaq:NXTC - BollyInsideNextCure to Host Virtual R&D Update Event on March 4, 2021 Nasdaq:NXTC - BollyInside
bollyinside.com - March 2 at 9:58 PM
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021 - GlobeNewswireREMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021 - GlobeNewswire
globenewswire.com - March 2 at 4:58 PM
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
finance.yahoo.com - March 2 at 4:58 PM
Would ApoE Make a Better Therapeutic Target Than Aβ? | ALZFORUM - AlzforumWould ApoE Make a Better Therapeutic Target Than Aβ? | ALZFORUM - Alzforum
alzforum.org - February 27 at 8:19 AM
NextCure to Host Virtual R&D Update Event on March 4, 2021 - Yahoo FinanceNextCure to Host Virtual R&D Update Event on March 4, 2021 - Yahoo Finance
finance.yahoo.com - February 26 at 6:31 PM
NextCure to Host Virtual R&D Update Event on March 4, 2021NextCure to Host Virtual R&D Update Event on March 4, 2021
finance.yahoo.com - February 26 at 6:31 PM
Krensavage Asset Management, LLC Buys NextCure Inc, Sells United Therapeutics Corp - Yahoo FinanceKrensavage Asset Management, LLC Buys NextCure Inc, Sells United Therapeutics Corp - Yahoo Finance
finance.yahoo.com - February 17 at 12:45 PM
Feb 17, 2021 - Krensavage Asset Management, LLC Buys NextCure Inc, Sells United Therapeutics Corp - GuruFocus.comFeb 17, 2021 - Krensavage Asset Management, LLC Buys NextCure Inc, Sells United Therapeutics Corp - GuruFocus.com
gurufocus.com - February 17 at 7:45 AM
Clinical Trials Market By 2029 Top Winning Strategies, COVID-19 Impacting Factors, Business Strategies | Future Market Insights – FLA News - FLA NewsClinical Trials Market By 2029 Top Winning Strategies, COVID-19 Impacting Factors, Business Strategies | Future Market Insights – FLA News - FLA News
flanewsonline.com - February 16 at 3:02 PM
DateCompanyBrokerageAction
2/25/2021VistaGen TherapeuticsJefferies Financial GroupInitiated Coverage
1/4/2021VistaGen TherapeuticsWilliam BlairUpgrade
12/22/2020VistaGen TherapeuticsMaxim GroupBoost Price Target
10/8/2020VistaGen TherapeuticsAegisInitiated Coverage
12/2/2019VistaGen TherapeuticsChardan CapitalReiterated Rating
11/4/2018VistaGen TherapeuticsOppenheimerSet Price Target
11/12/2020RedHill BiopharmaRoth CapitalLower Price Target
10/13/2020RedHill BiopharmaAscendiant Capital MarketsReiterated Rating
9/11/2020RedHill BiopharmaBTIG ResearchInitiated Coverage
3/5/2020RedHill BiopharmaHC WainwrightReiterated Rating
7/12/2019RedHill BiopharmaWBB SecuritiesUpgrade
12/12/2018RedHill BiopharmaLADENBURG THALM/SH SHSet Price Target
4/16/2021ImmunicWedbushReiterated Rating
3/30/2021ImmunicJMP SecuritiesInitiated Coverage
3/7/2021ImmunicSVB LeerinkReiterated Rating
8/25/2020ImmunicPiper SandlerInitiated Coverage
8/3/2020ImmunicBMO Capital MarketsBoost Price Target
2/25/2021Tonix PharmaceuticalsAlliance Global PartnersBoost Price Target
7/27/2018Tonix PharmaceuticalsBrookline Capital ManagementDowngrade
7/27/2018Tonix PharmaceuticalsB. RileyReiterated Rating
3/9/2021NextCureTruist SecuritiesUpgrade
1/15/2021NextCureBank of AmericaDowngrade
8/7/2020NextCureNeedham & Company LLCReiterated Rating
7/16/2020NextCureBenchmarkUpgrade
7/13/2020NextCureMorgan StanleyDowngrade
7/13/2020NextCureSunTrust BanksDowngrade
(Data available from 4/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.